First Citizens Bank & Trust Co. Purchases Shares of 9,343 USANA Health Sciences, Inc. $USNA

First Citizens Bank & Trust Co. purchased a new stake in USANA Health Sciences, Inc. (NYSE:USNA) during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 9,343 shares of the company’s stock, valued at approximately $285,000. First Citizens Bank & Trust Co. owned 0.05% of USANA Health Sciences as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in USNA. Pzena Investment Management LLC increased its position in USANA Health Sciences by 9.4% in the 2nd quarter. Pzena Investment Management LLC now owns 1,198,260 shares of the company’s stock valued at $36,583,000 after acquiring an additional 103,074 shares during the period. Jacobs Levy Equity Management Inc. increased its position in USANA Health Sciences by 46.2% in the 1st quarter. Jacobs Levy Equity Management Inc. now owns 188,511 shares of the company’s stock valued at $5,084,000 after acquiring an additional 59,535 shares during the period. Nuveen LLC acquired a new position in USANA Health Sciences in the 1st quarter valued at about $895,000. Charles Schwab Investment Management Inc. increased its position in USANA Health Sciences by 23.5% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 173,997 shares of the company’s stock valued at $4,693,000 after acquiring an additional 33,141 shares during the period. Finally, Teacher Retirement System of Texas acquired a new position in USANA Health Sciences in the 1st quarter valued at about $888,000. Institutional investors and hedge funds own 54.25% of the company’s stock.

USANA Health Sciences Price Performance

Shares of NYSE:USNA opened at $20.88 on Monday. The business’s 50 day simple moving average is $27.87 and its 200-day simple moving average is $28.96. The firm has a market capitalization of $381.39 million, a price-to-earnings ratio of 23.72, a price-to-earnings-growth ratio of 1.00 and a beta of 0.61. USANA Health Sciences, Inc. has a 12 month low of $18.69 and a 12 month high of $41.83.

USANA Health Sciences (NYSE:USNA) last announced its quarterly earnings results on Thursday, October 9th. The company reported $0.56 EPS for the quarter. The business had revenue of $200.22 million for the quarter. USANA Health Sciences had a return on equity of 6.96% and a net margin of 1.86%. USANA Health Sciences has set its Q3 2025 guidance at -0.150–0.150 EPS. On average, equities analysts anticipate that USANA Health Sciences, Inc. will post 2.45 earnings per share for the current year.

Insider Activity at USANA Health Sciences

In other news, insider David Mulham Mulham sold 3,515 shares of the business’s stock in a transaction that occurred on Wednesday, July 30th. The stock was sold at an average price of $30.26, for a total transaction of $106,363.90. Following the sale, the insider owned 9,260 shares of the company’s stock, valued at $280,207.60. The trade was a 27.51% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Gilbert A. Fuller sold 1,058 shares of the business’s stock in a transaction that occurred on Thursday, August 7th. The stock was sold at an average price of $29.10, for a total value of $30,787.80. The disclosure for this sale can be found here. 0.63% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

USNA has been the topic of several recent research reports. Wall Street Zen cut USANA Health Sciences from a “buy” rating to a “hold” rating in a research report on Saturday, October 11th. Zacks Research lowered USANA Health Sciences from a “hold” rating to a “strong sell” rating in a report on Tuesday, October 21st. Finally, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of USANA Health Sciences in a report on Friday. Two investment analysts have rated the stock with a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Reduce” and a consensus price target of $36.00.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.